KBB-Forum 2017 , Cilt 16, Sayı 1


Dr. Mustafa SAĞIT1, Dr. İbrahim HIRA1, Dr. Halil POLAT2, Dr. Zehra BEŞTEPE DURSUN3, Dr. İlhami ÇELİK3, Dr. Hafize SAV4, Dr. Hatice KARAMAN5, Dr. İbrahim ÖZCAN1
1Kayseri Eğitim ve Araştırma Hastanesi, Kulak Burun Boğaz Kliniği, Kayseri, Türkiye
2Yozgat Devlet Hastanesi, Kulak Burun Boğaz Kliniği, Yozgat, Türkiye
3Kayseri Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Kayseri, Türkiye
4Kayseri Eğitim ve Araştırma Hastanesi, Tıbbi Mikoloji Kliniği, Kayseri, Türkiye
5Kayseri Eğitim ve Araştırma Hastanesi, Tıbbi Patoloji Kliniği, Kayseri, Türkiye
Mucormycosis is an aggressive, angioinvasive and acute onset fungal disorder that can be fatal. It may lead infection in individuals with intact immune system although it often causes opportunistic fatal infection in situations leading immune deficiency such as diabetes mellitus, leukemia, antibiotic therapy, anti-neoplastic agent use, immunosuppressive therapy, corticosteroid use, protein-calorie malnutrition, organ transplantation, AIDS or substance abuse.

In this study, we presented diagnosis, treatment and follow-up modalities in 6 patients who presented to ENT and Infectious Disease outpatient clinics and diagnosed as mucormycosis between December, 2013 and March, 2016 in the shed of currently available literature. Keywords : Mucormycosis, cranial neuropathy, diabetes mellitus, antifungal agents